NCT06500442View on ClinicalTrials.gov

A Study to Assess NEU-111 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 17, 2024

Primary Completion Date

February 22, 2025

Study Completion Date

February 22, 2025

Conditions
Healthy
Interventions
DRUG

NEU-111

Oral Doses

DRUG

Placebo

Oral Doses

Trial Locations (1)

Unknown

New Zealand Clinical Research, Auckland

Sponsors

Lead Sponsor

Neuron23 Inc.
All Listed Sponsors
lead

Neuron23 Inc.

INDUSTRY

NCT06500442 - A Study to Assess NEU-111 in Healthy Participants | Biotech Hunter | Biotech Hunter